Immunome Inc (IMNM) Stock Price, Quote & News

Company Profile

Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It...

Industry: Biotechnology

Sector: Healthcare

Phone: 425 939 7410

Website: immunome.com

Address:

18702 North Creek Parkway, Suite 100, Bothell, United States

HunterT Apr. 16 at 9:07 PM

$IMNM don’t be shocked when this gets bought out for $80 a share like seagen was

0 · Reply

OfficialStocktwitsUser Apr. 15 at 9:56 PM

$IMNM RSI: 67.50, MACD: 0.3523 Vol: 1.14, MA20: 21.30, MA50: 21.98 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

Cycle144 Apr. 15 at 1:14 PM

$IMNM< 'Breakout Points to Higher Highs Ahead' -Bull pennant breakout - continuation of recovery -Strong demand confirmed by volume spike #Immunome #Bio https://www.fxempire.com/forecasts/article/immunome-imnm-price-forecast-breakout-points-to-higher-highs-ahead-1591674

1 · Reply

HunterT Apr. 14 at 3:38 PM

$IMNM $30S please

0 · Reply

vergeband Apr. 10 at 12:22 PM

@stockwatcherking can I ask what you think about $IMNM i work in oncology and I like their pipeline. Just getting started with investing. Said I would never do biotech again but this company is scooping up good people.

3 · Reply

EingeLTrade Apr. 1 at 8:29 PM

Up from here❔🤔 $IMNM

0 · Reply

TrendEdgeLogan Mar. 31 at 5:21 PM

$GH $KYMR $IMNM $NAMS $SOPH OCS PVLA ZYM SRZN ^^ best of the best healthcare / biotech names right now

0 · Reply

TradeMechanics_ Mar. 31 at 2:24 PM

Insider signal just dropped on $IMNM CEO Clay B. Siegall stepped in and bought 25,450 shares on the open market, with a weighted average price of $19.67 (range: $19.63–$19.70). That’s not a small gesture—that’s conviction buying from the top. When leadership puts real capital to work at these levels, it often signals alignment with the company’s outlook. Insiders don’t chase headlines—they buy when they believe the current price undervalues the story. Is this a bottom signal or just confidence in execution ahead? Either way, it’s a datapoint worth watching closely.

0 · Reply

CEOBuysDisclosures Mar. 31 at 1:15 PM

$IMNM CEO purchased 25,450 shares at $19.67 for a total of $500,602. SIEGALL CLAY B now owns 690,704 shares. https://ceo-buys.com

0 · Reply

FilingTracker Mar. 31 at 11:13 AM

$IMNM $500K insider purchase by President and CEO: https://www.sec.gov/Archives/edgar/data/1167496/000116749626000003/xslF345X06/form4-03312026_110335.xml

0 · Reply

Immunome Announces Oral Presentation of Phase 3 RINGSIDE Data at 2026 ASCO Annual Meeting

Apr 14, 2026, 4:54 PM EDT - 11 days ago

Immunome (IMNM) Price Forecast: Breakout Points to Higher Highs Ahead

Apr 2, 2026, 4:00 PM EDT - 23 days ago

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 10, 2026, 3:00 PM EDT - 6 weeks ago

Immunome Transcript: Leerink Global Healthcare Conference 2026

Mar 3, 2026, 4:02 PM EST - 7 weeks ago

Immunome Reports Full Year 2025 Financial Results and Provides Business Update

Mar 3, 2026, 9:50 AM EST - 7 weeks ago

Immunome Transcript: TD Cowen 46th Annual Health Care Conference

Feb 23, 2026, 8:00 AM EST - 2 months ago

Immunome to Present at Upcoming Investor Conferences

Feb 11, 2026, 9:00 AM EST - 2 months ago

Immunome Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Feb 4, 2026, 8:00 AM EST - 2 months ago

Immunome to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

Jan 14, 2026, 1:30 PM EST - 3 months ago

Immunome Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 6, 2026, 8:00 AM EST - 3 months ago

Immunome to Present at 44th Annual J.P. Morgan Healthcare Conference

Dec 16, 2025, 8:16 PM EST - 4 months ago

Immunome Announces Pricing of Public Offering of Common Stock

Dec 15, 2025, 4:01 PM EST - 4 months ago

Immunome Announces Proposed Public Offering of Common Stock

Dec 15, 2025, 8:30 AM EST - 4 months ago

Immunome Transcript: Study Result

Dec 15, 2025, 7:16 AM EST - 4 months ago

Immunome's experimental drug meets main goal in late-stage study

Dec 15, 2025, 7:00 AM EST - 4 months ago

Immunome Announces Positive Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors

Dec 14, 2025, 4:00 PM EST - 4 months ago

Immunome to Announce Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors

Dec 3, 2025, 9:10 AM EST - 5 months ago

Immunome Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 3, 2025, 9:00 AM EST - 5 months ago

Immunome Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 11, 2025, 8:30 AM EST - 5 months ago

Immunome Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 6, 2025, 4:05 PM EST - 6 months ago

Immunome Reports Third Quarter 2025 Financial Results and Provides Business Update

Oct 31, 2025, 11:51 AM EDT - 6 months ago

Immunome to Present at 2nd Annual Guggenheim Healthcare Innovation Conference

Oct 23, 2025, 12:00 PM EDT - 6 months ago

Immunome Presents Preclinical Data Showing Proprietary TOP1i ADC Payload HC74 Overcomes Multiple Mechanisms of ADC Resistance

Sep 18, 2025, 8:00 AM EDT - 7 months ago

Infinimmune Announces Research Collaboration with Immunome

Sep 9, 2025, 1:00 PM EDT - 8 months ago

Immunome Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 8:00 AM EDT - 8 months ago

Immunome to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 6, 2025, 4:05 PM EDT - 9 months ago

Immunome Reports Second Quarter 2025 Financial Results and Provides Business Update

Jun 10, 2025, 2:00 PM EDT - 11 months ago

Immunome Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

May 27, 2025, 9:30 AM EDT - 11 months ago

Immunome Transcript: TD Cowen's 6th Annual Oncology Innovation Summit

May 12, 2025, 4:05 PM EDT - 1 year ago

Immunome Reports First Quarter 2025 Financial Results and Provides Business Update

Apr 10, 2025, 12:45 PM EDT - 1 year ago

Immunome Transcript: 24th Annual Needham Virtual Healthcare Conference

Apr 4, 2025, 8:00 AM EDT - 1 year ago

Immunome to Present at the 24th Annual Needham Virtual Healthcare Conference

Mar 19, 2025, 4:05 PM EDT - 1 year ago

Immunome Reports Full Year 2024 Financial Results and Provides Business Update

Mar 10, 2025, 1:40 PM EDT - 1 year ago

Immunome Transcript: Leerink Global Healthcare Conference 2025

Mar 10, 2025, 7:41 AM EDT - 1 year ago

Immunome Doses First Patient in Phase 1 Trial of IM-1021, a ROR1-Targeted ADC

Mar 4, 2025, 1:10 PM EST - 1 year ago

Immunome Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 25, 2025, 8:00 AM EST - 1 year ago

Immunome to Present at Upcoming March Conferences

Jan 31, 2025, 4:01 PM EST - 1 year ago

Immunome Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Jan 29, 2025, 11:11 PM EST - 1 year ago

Immunome Announces Pricing of Upsized Public Offering of Common Stock

Jan 15, 2025, 12:45 PM EST - 1 year ago

Immunome Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 13, 2025, 8:00 AM EST - 1 year ago

Immunome Provides Pipeline Update in Advance of Presentation at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 3, 2024, 4:30 PM EST - 1 year ago

Immunome Transcript: Piper Sandler 36th Annual Healthcare Conference

Nov 27, 2024, 8:00 AM EST - 1 year ago

Immunome to Present at the Piper Sandler 36th Annual Healthcare Conference

Nov 13, 2024, 4:05 PM EST - 1 year ago

Immunome Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 13, 2024, 10:30 AM EST - 1 year ago

Immunome Transcript: Guggenheim Securities Inaugural Healthcare Innovation Conference

Nov 5, 2024, 8:00 AM EST - 1 year ago

Immunome to Present at Guggenheim's Inaugural Healthcare Innovation Conference

Oct 29, 2024, 8:00 AM EDT - 1 year ago

Immunome Presents Compelling Preclinical Data Demonstrating Robust Anti-Tumor Activity for IM-1021

Oct 18, 2024, 8:00 AM EDT - 1 year ago

Immunome to Present Poster Highlighting Preclinical Evaluation of IM-1021, a ROR1-Targeted Antibody Drug Conjugate, at the 36th EORTC-NCI-AACR Symposium

Oct 8, 2024, 8:05 AM EDT - 1 year ago

Immunome Appoints Roee Shahar as Executive Vice President, Commercial

Sep 13, 2024, 7:00 AM EDT - 1 year ago

Immunome to Present Updated Results for RINGSIDE Phase 2 Trial of AL102 for the Treatment of Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024

Sep 4, 2024, 5:35 PM EDT - 1 year ago

Immunome Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 29, 2024, 8:00 AM EDT - 1 year ago

Immunome to Present at Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 12, 2024, 4:01 PM EDT - 1 year ago

Immunome Reports Second Quarter 2024 Financial Results and Provides Business Update

Jul 25, 2024, 8:00 AM EDT - 1 year ago

Immunome Provides Update on Recent Business Development Activity Expected to Expand ADC Capabilities

Jun 27, 2024, 8:00 AM EDT - 1 year ago

Immunome Appoints Phil Tsai as Chief Technical Officer

May 20, 2024, 8:00 AM EDT - 2 years ago

Immunome Announces Completion of Purchase of Assets from Atreca

May 17, 2024, 8:00 AM EDT - 2 years ago

Immunome Announces Promotion of Max Rosett to Chief Financial Officer

May 14, 2024, 8:00 AM EDT - 2 years ago

Immunome Reports First Quarter 2024 Financial Results and Provides Business Update

May 8, 2024, 8:00 AM EDT - 2 years ago

Immunome to Present at 2024 Bank of America Healthcare Conference

May 2, 2024, 8:00 AM EDT - 2 years ago

Immunome Appoints Kinney Horn as Chief Business Officer

Apr 25, 2024, 8:26 AM EDT - 2 years ago

Immunome Appoints Sandra M. Swain to Board of Directors

Apr 5, 2024, 8:00 AM EDT - 2 years ago

Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting

Mar 28, 2024, 4:02 PM EDT - 2 years ago

Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets

Mar 26, 2024, 8:00 AM EDT - 2 years ago

Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala

Mar 18, 2024, 5:44 AM EDT - 2 years ago

Arrayjet's ArrayPlex Platform Selected by Immunome for Use in Its Discovery of Targeted Cancer Therapies

Mar 7, 2024, 8:00 AM EST - 2 years ago

Immunome to Participate in the Leerink Partners Global Biopharma Conference

Mar 1, 2024, 8:00 AM EST - 2 years ago

Immunome to Participate in the TD Cowen 44th Annual Healthcare Conference

Feb 20, 2024, 8:15 AM EST - 2 years ago

Immunome Recognizes Ayala Pharmaceuticals' Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors

HunterT Apr. 16 at 9:07 PM

$IMNM don’t be shocked when this gets bought out for $80 a share like seagen was

0 · Reply

OfficialStocktwitsUser Apr. 15 at 9:56 PM

0 · Reply

Cycle144 Apr. 15 at 1:14 PM

1 · Reply

HunterT Apr. 14 at 3:38 PM

$IMNM $30S please

0 · Reply

vergeband Apr. 10 at 12:22 PM

3 · Reply

EingeLTrade Apr. 1 at 8:29 PM

Up from here❔🤔 $IMNM

0 · Reply

TrendEdgeLogan Mar. 31 at 5:21 PM

$GH $KYMR $IMNM $NAMS $SOPH OCS PVLA ZYM SRZN ^^ best of the best healthcare / biotech names right now

0 · Reply

TradeMechanics_ Mar. 31 at 2:24 PM

0 · Reply

CEOBuysDisclosures Mar. 31 at 1:15 PM

$IMNM CEO purchased 25,450 shares at $19.67 for a total of $500,602. SIEGALL CLAY B now owns 690,704 shares. https://ceo-buys.com

0 · Reply

FilingTracker Mar. 31 at 11:13 AM

$IMNM $500K insider purchase by President and CEO: https://www.sec.gov/Archives/edgar/data/1167496/000116749626000003/xslF345X06/form4-03312026_110335.xml

0 · Reply

RadioIsotope25 Mar. 28 at 1:42 PM

Radiopharm Theranostics (ASX: RAD) Investor Webinar -- RAD 101 Phase 2b second interim data - Zoom $RADX $ARTL $DRTS $IMNM https://us02web.zoom.us/rec/play/jHo4QT2d91u1IuLLzNdkfW7O01zHB8XV7X4-USlV2y-4TPZFkHt4U3BZJIlXY9cRVVMI-WgS-3Ji3Rtg.dh4n_6T8eCGOud-B

3 · Reply

RadioIsotope25 Mar. 23 at 11:08 PM

$RADX Meets 90% news just broke on RAD101 $IMNM $AKTS

0 · Reply

Jeff9905 Mar. 19 at 5:41 PM

$IMNM so they have tripled their employee count in the last 18 months. Why can't they get anything to the finish line?

0 · Reply

RadioIsotope25 Mar. 15 at 3:23 PM

Radiopharmaceutical buyouts and Market Caps $RADX $IMNM $PYXS $CELC

1 · Reply

RadioIsotope25 Mar. 13 at 4:43 PM

Diamond in the Rough $RADX $PYXS $IMNM $SMMT $AKTS

0 · Reply

EingeLTrade Mar. 10 at 1:56 PM

Added more $IMNM

0 · Reply

RadioIsotope25 Mar. 6 at 12:18 AM

$30 target @ Jones Trading for Radiopharm Theranostics. $IMNM $PYXS $SLS $IOVA $RADX

3 · Reply

OfficialStocktwitsUser Mar. 4 at 2:57 PM

$IMNM RSI: 41.24, MACD: -0.3808 Vol: 1.37, MA20: 22.85, MA50: 22.76 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

d_risk Mar. 3 at 9:27 PM

$IMNM - Immunome Inc - 10K - Updated Risk Factors IMNM’s 2026 10-K sharpens early-stage and financing risk (no NDA/BLA, no near-term revenue, capital-intensive R&D) while adding program-specific IM‑3050 uncertainty, heavier dependence on ADC platform and in-licensed IP, broader global/regulatory and orphan/companion diagnostic hurdles, deeper patent and trademark vulnerability, expanded misconduct and anti-takeover concerns, and new litigation and Nasdaq compliance risks, even as some prior funding, foreign market, and analyst-coverage risks are pared back or reframed. #PharmaceuticalCommercialization #CompetitiveRisk #SupplyChainRisk #RegulatoryUncertainty #Biotechnology #EarlyStageRisk #CapitalIntensiveR&D #RegulatoryChallenges #IntellectualPropertyRisk 🟢 Added 🟠 Removed https://d-risk.ai/IMNM/10-K/2026-03-03

0 · Reply

d_risk Mar. 3 at 9:21 PM

0 · Reply

RadioIsotope25 Feb. 28 at 4:39 PM

$RADX Terbium and Lutetium $AKTS $CATX $IMNM https://youtu.be/AOalQM8zfDM

0 · Reply

BillionerOfKing Feb. 25 at 12:41 AM

$IMNM Current Stock Price: $22.11 Contracts to trade: $22.0 IMNM Mar 20 2026 Call Entry: $0.65 Exit: $0.91 ROI: 39% Hold ~26 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

Market Cap	2.67B
Revenue (ttm)	6.94M
Net Income (ttm)	-212.39M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-3,060.37%
Debt to Equity Ratio	0.00

Volume	590,100
Avg Vol	1,200,878
Day's Range	N/A - N/A
Shares Out	113.13M
Stochastic %K	44%
Beta	2.13
Analysts	Strong Sell
Price Target	$35.54